Symbols / IMTX $11.26 +0.72% Immatics N.V.
IMTX Chart
About
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Fundamentals
Scroll to Statements| Market Cap | 1.51B | Enterprise Value | 1.06B | Income | -196.45M | Sales | 48.27M | Book/sh | 4.26 | Cash/sh | 3.50 |
| Dividend Yield | — | Payout | 0.00% | Employees | 589 | IPO | — | P/E | — | Forward P/E | -6.35 |
| PEG | — | P/S | 31.28 | P/B | 2.64 | P/C | — | EV/EBITDA | -6.11 | EV/Sales | 21.88 |
| Quick Ratio | 11.07 | Current Ratio | 11.72 | Debt/Eq | 3.23 | LT Debt/Eq | — | EPS (ttm) | -1.90 | EPS next Y | -1.77 |
| EPS Growth | — | Revenue Growth | -64.90% | Earnings | 2026-05-06 | ROA | -18.08% | ROE | -37.10% | ROIC | — |
| Gross Margin | -280.87% | Oper. Margin | -196.76% | Profit Margin | 0.00% | Shs Outstand | 134.10M | Shs Float | 67.27M | Short Float | 5.63% |
| Short Ratio | 8.54 | Short Interest | — | 52W High | 12.41 | 52W Low | 3.94 | Beta | 1.34 | Avg Volume | 444.06K |
| Volume | 176.81K | Target Price | $18.75 | Recom | Strong_buy | Prev Close | $11.18 | Price | $11.26 | Change | 0.72% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-11-19 | main | Mizuho | Outperform → Outperform | $23 |
| 2025-11-18 | main | Guggenheim | Buy → Buy | $19 |
| 2025-09-18 | init | Guggenheim | — → Buy | $16 |
| 2025-05-28 | init | Deutsche Bank | — → Buy | $10 |
| 2025-04-01 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2024-11-19 | main | B of A Securities | Buy → Buy | $15 |
| 2024-10-07 | init | Piper Sandler | — → Overweight | $19 |
| 2024-09-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-09-05 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-05-16 | main | Mizuho | Buy → Buy | $16 |
| 2023-11-02 | init | Cantor Fitzgerald | — → Overweight | — |
| 2023-03-31 | init | Mizuho | — → Buy | $12 |
| 2023-03-23 | main | Chardan Capital | — → Buy | $25 |
| 2022-08-10 | main | Chardan Capital | — → Buy | $28 |
| 2022-06-03 | main | SVB Leerink | — → Outperform | $26 |
| 2022-03-24 | main | SVB Leerink | — → Outperform | $25 |
| 2021-07-15 | main | SVB Leerink | — → Outperform | $27 |
| 2021-03-17 | main | SVB Leerink | — → Outperform | $26 |
| 2020-09-22 | init | Goldman Sachs | — → Buy | $17 |
- Four cancer studies put Immatics’ cell therapies on ASCO stage - Stock Titan ue, 21 Apr 2026 14
- Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat Sat, 18 Apr 2026 08
- Immatics (IMTX) Is Up 7.1% After Pediatric PRAME TCR Remission Case And AACR Spotlight - Has The Bull Case Changed? - simplywall.st Sat, 18 Apr 2026 16
- Immatics (IMTX) Showcases Pediatric Patient Breakthrough at AACR 2026 - GuruFocus Sat, 18 Apr 2026 01
- What do insiders think about Immatics N.V. (IMTX) Stock | Price at $10.32, Up 0.68% - Global Trading Community - UBND thành phố Hải Phòng Wed, 08 Apr 2026 07
- Price-Driven Insight from (IMTX) for Rule-Based Strategy - Stock Traders Daily hu, 16 Apr 2026 19
- What do insiders think about Immatics N.V. (IMTX) Stock | Price at $10.32, Up 0.68% - Long Setup - Xã Vĩnh Công Wed, 08 Apr 2026 07
- What is the sentiment around Immatics N.V. (IMTX) Stock | Price at $10.35, Up 3.40% - Large Cap Trends - Cổng thông tin điện tử tỉnh Lào Cai hu, 02 Apr 2026 07
- Teen’s metastatic kidney cancer in remission 6 months after Immatics therapy - Stock Titan Fri, 17 Apr 2026 19
- A Look At Immatics (IMTX) Valuation After Promising PRAME TCR Remission Data In Pediatric Cancer - simplywall.st Sun, 19 Apr 2026 20
- Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering - Quiver Quantitative Fri, 05 Dec 2025 08
- Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX) - Seeking Alpha Mon, 09 Mar 2026 07
- (IMTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily Sun, 05 Apr 2026 18
- IMTX Stock Analysis: Immatics N.V. Ordinary Shares rises 3.4 percent to 10.35 in biotech uptrend - Xã Châu Thành Fri, 03 Apr 2026 07
- SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX - MarketBeat Sun, 05 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
48.27
-69.03%
|
155.84
+188.60%
|
54.00
-68.76%
|
172.83
|
| Operating Revenue |
|
48.27
-69.03%
|
155.84
+188.60%
|
54.00
-68.76%
|
172.83
|
| Operating Expense |
|
230.28
+18.43%
|
194.45
+24.87%
|
155.72
+8.99%
|
142.88
|
| Research And Development |
|
183.83
+24.14%
|
148.08
+24.79%
|
118.66
+11.13%
|
106.78
|
| Selling General And Administration |
|
51.18
+10.19%
|
46.45
+21.60%
|
38.20
+5.74%
|
36.12
|
| General And Administrative Expense |
|
51.18
+10.19%
|
46.45
+21.60%
|
38.20
+5.74%
|
36.12
|
| Salaries And Wages |
|
26.29
+11.93%
|
23.48
+7.83%
|
21.78
+4.10%
|
20.92
|
| Other Gand A |
|
24.90
+8.42%
|
22.96
-39.88%
|
38.20
+5.74%
|
36.12
|
| Other Operating Expenses |
|
-4.73
-5969.23%
|
-0.08
+93.15%
|
-1.14
-4280.77%
|
-0.03
|
| Total Expenses |
|
230.28
+18.43%
|
194.45
+24.87%
|
155.72
+8.99%
|
142.88
|
| Operating Income |
|
-182.02
-371.36%
|
-38.62
+62.04%
|
-101.72
-439.60%
|
29.95
|
| Total Operating Income As Reported |
|
-182.02
-371.36%
|
-38.62
+62.04%
|
-101.72
-439.60%
|
29.95
|
| EBITDA |
|
-185.09
-637.16%
|
34.46
+138.75%
|
-88.93
-277.71%
|
50.04
|
| Normalized EBITDA |
|
-152.44
-10874.59%
|
-1.39
+98.28%
|
-80.65
-304.70%
|
39.40
|
| Reconciled Depreciation |
|
12.40
+1.43%
|
12.22
+68.99%
|
7.23
+3.83%
|
6.97
|
| EBIT |
|
-197.49
-988.31%
|
22.23
+123.12%
|
-96.16
-323.25%
|
43.07
|
| Total Unusual Items |
|
-32.65
-191.09%
|
35.85
+532.77%
|
-8.28
-177.82%
|
10.64
|
| Total Unusual Items Excluding Goodwill |
|
-32.65
-191.09%
|
35.85
+532.77%
|
-8.28
-177.82%
|
10.64
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Restructuring And Mergern Acquisition |
|
—
|
—
|
—
|
0.00
|
| Net Income |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Pretax Income |
|
-198.44
-1029.62%
|
21.35
+122.01%
|
-96.99
-330.74%
|
42.04
|
| Net Non Operating Interest Income Expense |
|
16.23
-32.69%
|
24.11
+85.30%
|
13.01
+805.01%
|
1.44
|
| Interest Expense Non Operating |
|
0.95
+6.77%
|
0.89
+6.62%
|
0.83
-19.94%
|
1.04
|
| Net Interest Income |
|
16.23
-32.69%
|
24.11
+85.30%
|
13.01
+805.01%
|
1.44
|
| Interest Expense |
|
0.95
+6.77%
|
0.89
+6.62%
|
0.83
-19.94%
|
1.04
|
| Interest Income Non Operating |
|
17.18
-31.29%
|
25.00
+80.58%
|
13.85
+459.17%
|
2.48
|
| Interest Income |
|
17.18
-31.29%
|
25.00
+80.58%
|
13.85
+459.17%
|
2.48
|
| Other Income Expense |
|
-32.65
-191.09%
|
35.85
+532.77%
|
-8.28
-177.82%
|
10.64
|
| Gain On Sale Of Security |
|
-32.65
-191.09%
|
35.85
+532.77%
|
-8.28
-177.82%
|
10.64
|
| Tax Provision |
|
-1.99
-132.46%
|
6.13
+361.32%
|
-2.35
-116.36%
|
14.33
|
| Tax Rate For Calcs |
|
0.00
-96.51%
|
0.00
+1087.41%
|
0.00
-92.91%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-0.33
-103.18%
|
10.29
+5238.75%
|
-0.20
-105.52%
|
3.63
|
| Net Income Including Noncontrolling Interests |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Net Income From Continuing Operation Net Minority Interest |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Net Income From Continuing And Discontinued Operation |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Net Income Continuous Operations |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Minority Interests |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
-164.12
-1487.65%
|
-10.34
+88.06%
|
-86.57
-518.43%
|
20.69
|
| Net Income Common Stockholders |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Diluted EPS |
|
—
|
0.14
+111.86%
|
-1.18
-314.55%
|
0.55
|
| Basic EPS |
|
—
|
0.14
+111.86%
|
-1.18
-310.71%
|
0.56
|
| Basic Average Shares |
|
—
|
105.74
+31.28%
|
80.55
+20.24%
|
66.99
|
| Diluted Average Shares |
|
—
|
106.80
+32.59%
|
80.55
+18.09%
|
68.21
|
| Diluted NI Availto Com Stockholders |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
562.34
-19.22%
|
696.15
+36.51%
|
509.96
+25.05%
|
407.82
|
| Current Assets |
|
504.01
-19.94%
|
629.55
+40.10%
|
449.37
+19.15%
|
377.15
|
| Cash Cash Equivalents And Short Term Investments |
|
469.34
-22.35%
|
604.45
+41.93%
|
425.89
+17.58%
|
362.20
|
| Cash And Cash Equivalents |
|
345.92
+46.11%
|
236.75
+8.37%
|
218.47
+47.10%
|
148.52
|
| Other Short Term Investments |
|
123.42
-66.44%
|
367.70
+77.27%
|
207.42
-2.93%
|
213.69
|
| Receivables |
|
6.88
+2.02%
|
6.75
+17.57%
|
5.74
+416.38%
|
1.11
|
| Accounts Receivable |
|
6.10
+4.13%
|
5.86
+43.10%
|
4.09
+268.41%
|
1.11
|
| Other Receivables |
|
—
|
—
|
—
|
—
|
| Taxes Receivable |
|
0.78
-11.94%
|
0.89
-45.99%
|
1.64
+59.46%
|
1.03
|
| Prepaid Assets |
|
12.92
+7.24%
|
12.05
+13.46%
|
10.62
+1.62%
|
10.45
|
| Hedging Assets Current |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
14.87
+135.66%
|
6.31
-11.36%
|
7.12
-48.55%
|
13.84
|
| Total Non Current Assets |
|
58.33
-12.41%
|
66.59
+9.90%
|
60.59
+97.60%
|
30.67
|
| Net PPE |
|
54.90
-13.84%
|
63.71
+11.67%
|
57.05
+115.39%
|
26.49
|
| Gross PPE |
|
84.66
-11.61%
|
95.78
+19.84%
|
79.92
+70.15%
|
46.97
|
| Accumulated Depreciation |
|
-29.76
+7.17%
|
-32.06
-40.23%
|
-22.86
-11.63%
|
-20.48
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
12.59
-4.30%
|
13.15
+2.37%
|
12.85
+3.55%
|
12.41
|
| Machinery Furniture Equipment |
|
8.90
-30.08%
|
12.73
+15.18%
|
11.05
+44.07%
|
7.67
|
| Other Properties |
|
34.41
-10.57%
|
38.48
+25.71%
|
30.61
-13.69%
|
35.47
|
| Leases |
|
28.76
-8.44%
|
31.42
+23.63%
|
25.41
+562.49%
|
3.84
|
| Goodwill And Other Intangible Assets |
|
1.58
-2.89%
|
1.63
+6.96%
|
1.52
-6.68%
|
1.63
|
| Other Intangible Assets |
|
1.58
-2.89%
|
1.63
+6.96%
|
1.52
-6.68%
|
1.63
|
| Non Current Prepaid Assets |
|
1.08
+224.62%
|
0.33
-76.45%
|
1.41
-25.81%
|
1.91
|
| Other Non Current Assets |
|
0.77
-16.14%
|
0.92
+52.07%
|
0.60
-76.31%
|
2.54
|
| Total Liabilities Net Minority Interest |
|
78.24
-35.50%
|
121.30
-58.51%
|
292.35
+42.98%
|
204.47
|
| Current Liabilities |
|
43.01
-36.73%
|
67.99
-56.57%
|
156.55
+47.06%
|
106.45
|
| Payables And Accrued Expenses |
|
21.18
-13.41%
|
24.46
-26.02%
|
33.06
+153.25%
|
13.06
|
| Payables |
|
2.69
-80.62%
|
13.88
-10.58%
|
15.52
+18.90%
|
13.06
|
| Accounts Payable |
|
0.34
-96.64%
|
10.11
+31.91%
|
7.67
-41.28%
|
13.06
|
| Current Accrued Expenses |
|
18.49
+74.77%
|
10.58
-39.68%
|
17.54
+80.62%
|
9.71
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.71
+8.11%
|
1.58
+23.65%
|
1.28
+58.44%
|
0.81
|
| Total Tax Payable |
|
2.35
-37.65%
|
3.77
-52.04%
|
7.86
+1.73%
|
7.72
|
| Income Tax Payable |
|
0.03
-98.18%
|
1.76
-59.03%
|
4.30
+0.00%
|
4.30
|
| Current Debt And Capital Lease Obligation |
|
2.76
-3.30%
|
2.85
+9.49%
|
2.60
+20.61%
|
2.16
|
| Current Capital Lease Obligation |
|
2.76
-3.30%
|
2.85
+9.49%
|
2.60
+20.61%
|
2.16
|
| Current Deferred Liabilities |
|
15.82
-55.95%
|
35.91
-64.24%
|
100.40
+54.57%
|
64.96
|
| Current Deferred Revenue |
|
15.82
-55.95%
|
35.91
-64.24%
|
100.40
+54.57%
|
64.96
|
| Other Current Liabilities |
|
1.55
-51.36%
|
3.19
-83.41%
|
19.21
-26.92%
|
26.28
|
| Total Non Current Liabilities Net Minority Interest |
|
35.23
-33.93%
|
53.32
-60.74%
|
135.79
+38.55%
|
98.02
|
| Long Term Debt And Capital Lease Obligation |
|
12.88
-3.55%
|
13.35
+4.33%
|
12.80
+3.18%
|
12.40
|
| Long Term Capital Lease Obligation |
|
12.88
-3.55%
|
13.35
+4.33%
|
12.80
+3.18%
|
12.40
|
| Non Current Deferred Liabilities |
|
22.35
-44.08%
|
39.97
-67.51%
|
122.99
+43.73%
|
85.57
|
| Non Current Deferred Revenue |
|
18.54
-45.72%
|
34.16
-70.43%
|
115.53
+52.49%
|
75.76
|
| Non Current Deferred Taxes Liabilities |
|
3.81
-34.41%
|
5.80
-22.26%
|
7.47
-23.90%
|
9.81
|
| Other Non Current Liabilities |
|
—
|
—
|
0.00
-90.48%
|
0.04
|
| Stockholders Equity |
|
484.10
-15.79%
|
574.84
+164.15%
|
217.62
+7.01%
|
203.35
|
| Common Stock Equity |
|
484.10
-15.79%
|
574.84
+164.15%
|
217.62
+7.01%
|
203.35
|
| Capital Stock |
|
1.34
+10.28%
|
1.22
+43.57%
|
0.85
+10.43%
|
0.77
|
| Common Stock |
|
1.34
+10.28%
|
1.22
+43.57%
|
0.85
+10.43%
|
0.77
|
| Share Issued |
|
134.07
+10.30%
|
121.55
+43.58%
|
84.66
+10.42%
|
76.67
|
| Ordinary Shares Number |
|
134.07
+10.30%
|
121.55
+43.58%
|
84.66
+10.42%
|
76.67
|
| Additional Paid In Capital |
|
1,277.34
+9.91%
|
1,162.14
+41.18%
|
823.17
+15.26%
|
714.18
|
| Retained Earnings |
|
-785.99
-33.32%
|
-589.54
+2.52%
|
-604.76
-18.55%
|
-510.11
|
| Gains Losses Not Affecting Retained Earnings |
|
-8.59
-933.37%
|
1.03
+163.02%
|
-1.64
-10.47%
|
-1.48
|
| Other Equity Adjustments |
|
-8.59
-933.37%
|
1.03
+163.02%
|
-1.64
-10.47%
|
-1.48
|
| Total Equity Gross Minority Interest |
|
484.10
-15.79%
|
574.84
+164.15%
|
217.62
+7.01%
|
203.35
|
| Total Capitalization |
|
484.10
-15.79%
|
574.84
+164.15%
|
217.62
+7.01%
|
203.35
|
| Working Capital |
|
461.00
-17.91%
|
561.57
+91.78%
|
292.82
+8.17%
|
270.70
|
| Invested Capital |
|
484.10
-15.79%
|
574.84
+164.15%
|
217.62
+7.01%
|
203.35
|
| Total Debt |
|
15.63
-3.51%
|
16.20
+5.20%
|
15.40
+5.77%
|
14.56
|
| Capital Lease Obligations |
|
15.63
-3.51%
|
16.20
+5.20%
|
15.40
+5.77%
|
14.56
|
| Net Tangible Assets |
|
482.52
-15.82%
|
573.21
+165.26%
|
216.09
+7.13%
|
201.72
|
| Tangible Book Value |
|
482.52
-15.82%
|
573.21
+165.26%
|
216.09
+7.13%
|
201.72
|
| Current Provisions |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-176.63
-11.77%
|
-158.03
-966.96%
|
18.23
-81.80%
|
100.13
|
| Cash Flow From Continuing Operating Activities |
|
-176.63
-11.77%
|
-158.03
-966.96%
|
18.23
-81.80%
|
100.13
|
| Net Income From Continuing Operations |
|
-196.45
-1390.89%
|
15.22
+116.08%
|
-94.65
-441.66%
|
27.70
|
| Depreciation Amortization Depletion |
|
12.40
+1.43%
|
12.22
+68.99%
|
7.23
+3.83%
|
6.97
|
| Depreciation And Amortization |
|
12.40
+1.43%
|
12.22
+68.99%
|
7.23
+3.83%
|
6.97
|
| Other Non Cash Items |
|
-16.23
+32.69%
|
-24.11
-85.30%
|
-13.01
-805.01%
|
-1.44
|
| Stock Based Compensation |
|
15.02
-14.89%
|
17.64
-14.79%
|
20.70
-8.26%
|
22.57
|
| Deferred Tax |
|
-1.99
-132.46%
|
6.13
+361.32%
|
-2.35
-116.36%
|
14.33
|
| Deferred Income Tax |
|
-1.99
-132.46%
|
6.13
+361.32%
|
-2.35
-116.36%
|
14.33
|
| Operating Gains Losses |
|
33.15
+192.17%
|
-35.97
-509.20%
|
8.79
+209.98%
|
-7.99
|
| Gain Loss On Investment Securities |
|
-1.73
+89.98%
|
-17.26
-930.40%
|
2.08
+118.99%
|
-10.95
|
| Net Foreign Currency Exchange Gain Loss |
|
34.13
+282.47%
|
-18.71
-372.64%
|
6.86
+132.34%
|
2.95
|
| Gain Loss On Sale Of PPE |
|
0.75
+74900.00%
|
0.00
+100.67%
|
-0.15
|
0.00
|
| Change In Working Capital |
|
-43.97
+70.84%
|
-150.78
-278.25%
|
84.59
+127.04%
|
37.26
|
| Change In Receivables |
|
-0.24
+86.28%
|
-1.76
+40.85%
|
-2.98
-595.10%
|
-0.43
|
| Changes In Account Receivables |
|
-0.24
+86.28%
|
-1.76
+40.85%
|
-2.98
-595.10%
|
-0.43
|
| Change In Payables And Accrued Expense |
|
—
|
—
|
—
|
—
|
| Change In Payable |
|
—
|
—
|
—
|
—
|
| Change In Account Payable |
|
—
|
—
|
—
|
—
|
| Change In Other Working Capital |
|
-37.62
+74.88%
|
-149.74
-274.12%
|
86.00
+88.76%
|
45.56
|
| Change In Other Current Assets |
|
-6.11
-940.17%
|
0.73
-53.78%
|
1.57
+119.98%
|
-7.87
|
| Investing Cash Flow |
|
204.79
+234.39%
|
-152.39
-385.49%
|
-31.39
+85.04%
|
-209.79
|
| Cash Flow From Continuing Investing Activities |
|
204.79
+234.39%
|
-152.39
-385.49%
|
-31.39
+85.04%
|
-209.79
|
| Net PPE Purchase And Sale |
|
-6.56
+59.69%
|
-16.27
+46.92%
|
-30.65
-439.03%
|
-5.69
|
| Purchase Of PPE |
|
-6.56
+59.70%
|
-16.27
+47.17%
|
-30.80
-436.75%
|
-5.74
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.00
-98.67%
|
0.15
+188.46%
|
0.05
|
| Capital Expenditure |
|
-6.80
+58.71%
|
-16.48
+46.76%
|
-30.96
-398.10%
|
-6.21
|
| Net Investment Purchase And Sale |
|
211.59
+255.69%
|
-135.91
-23292.25%
|
-0.58
+99.71%
|
-203.63
|
| Purchase Of Investment |
|
-338.27
+24.89%
|
-450.35
-8.43%
|
-415.32
-91.99%
|
-216.32
|
| Sale Of Investment |
|
549.86
+74.87%
|
314.44
-24.18%
|
414.74
+3166.99%
|
12.70
|
| Net Intangibles Purchase And Sale |
|
-0.25
-18.75%
|
-0.21
-31.65%
|
-0.16
+66.88%
|
-0.48
|
| Purchase Of Intangibles |
|
-0.25
-18.75%
|
-0.21
-31.65%
|
-0.16
+66.88%
|
-0.48
|
| Financing Cash Flow |
|
97.35
-69.55%
|
319.68
+278.25%
|
84.52
-31.68%
|
123.71
|
| Cash Flow From Continuing Financing Activities |
|
97.35
-69.55%
|
319.68
+278.25%
|
84.52
-31.68%
|
123.71
|
| Net Issuance Payments Of Debt |
|
-2.96
-47.07%
|
-2.01
+47.73%
|
-3.85
-35.39%
|
-2.84
|
| Repayment Of Debt |
|
-2.96
-47.07%
|
-2.01
+47.73%
|
-3.85
-35.39%
|
-2.84
|
| Long Term Debt Payments |
|
-2.96
-47.07%
|
-2.01
+47.73%
|
-3.85
-35.39%
|
-2.84
|
| Net Long Term Debt Issuance |
|
-2.96
-47.07%
|
-2.01
+47.73%
|
-3.85
-35.39%
|
-2.84
|
| Net Common Stock Issuance |
|
107.31
-68.72%
|
343.01
+279.42%
|
90.40
-32.78%
|
134.48
|
| Net Other Financing Charges |
|
-7.00
+67.17%
|
-21.31
-945.32%
|
-2.04
+74.29%
|
-7.93
|
| Changes In Cash |
|
125.51
+1254.42%
|
9.27
-87.01%
|
71.36
+407.87%
|
14.05
|
| Effect Of Exchange Rate Changes |
|
-16.34
-281.42%
|
9.01
+742.12%
|
-1.40
-195.12%
|
1.48
|
| Beginning Cash Position |
|
236.75
+8.37%
|
218.47
+47.10%
|
148.52
+11.67%
|
132.99
|
| End Cash Position |
|
345.92
+46.11%
|
236.75
+8.37%
|
218.47
+47.10%
|
148.52
|
| Free Cash Flow |
|
-183.43
-5.11%
|
-174.51
-1270.96%
|
-12.73
-113.55%
|
93.92
|
| Common Stock Issuance |
|
107.31
-68.72%
|
343.01
+279.42%
|
90.40
-32.78%
|
134.48
|
| Interest Paid CFO |
|
-0.95
-6.77%
|
-0.89
-205.52%
|
-0.29
+58.27%
|
-0.69
|
| Interest Received CFO |
|
26.82
+71.85%
|
15.61
+53.49%
|
10.17
+516.56%
|
1.65
|
| Issuance Of Capital Stock |
|
107.31
-68.72%
|
343.01
+279.42%
|
90.40
-32.78%
|
134.48
|
| Taxes Refund Paid |
|
-4.43
+66.18%
|
-13.10
-342.50%
|
-2.96
-1221.43%
|
-0.22
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|